Bempedoic Acid / Ezetimibe

ApprovedSmall molecule

Bempedoic Acid / Ezetimibe is one of 85 small molecule programs targeting Acute Coronary Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

Acute Coronary SyndromeApproved

Active, not recruiting

Type 2 Diabetes MellitusApproved

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Bempedoic Acid / Ezetimibe

EEsperion Therapeutics, Inc.

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Glargine

Eli Lilly

Preclinical

8 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

GLP-1

RRigshospitalet, Denmark

Preclinical

1 9

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 10

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Recruiting

Pregnancy

NCT05103254

Clinical

Trials by Indication[1]

Concentration1 trial

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

Completed·EEsperion Therapeutics, Inc.·Phase 4·NCT06021951·16 enrolled

Type 2 Diabetes1 trial

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Completed·EEsperion Therapeutics, Inc.·Phase 2·NCT03531905·242 enrolled

Pregnancy1 trial

Bempedoic Acid Pregnancy Surveillance Program

Recruiting·EEsperion Therapeutics, Inc.··NCT05103254·20 enrolled

Acute Coronary Syndrome1 trial

Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

Unknown status·KKaiser Permanente·Phase 4·NCT05263778·500 enrolled

Type 2 Diabetes Mellitus1 trial

Comparative Efficacy and Safety of Dual Versus Triple Lipid-Lowering Therapies (Rosuvastatin/Ezetimibe, Bempedoic Acid/Ezetimibe, and Rosuvastatin/Ezetimibe/Bempedoic Acid ) in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol

Recruiting·BBahria University·Approved·NCT07255820·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Bempedoic Acid / Ezetimibe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bempedoic Acid / Ezetimibe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bempedoic Acid / Ezetimibe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Esperion Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEsperion Therapeutics, Inc.

Bempedoic Acid / Ezetimibe

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Concentration1 trial

Type 2 Diabetes1 trial

Pregnancy1 trial

Acute Coronary Syndrome1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News